An interventional study of Brain Cooling in Concussion (Diagnosis), Concussion Post Syndrome and Concussion, Mild, sponsored by Penn State University. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 27 Years. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Penn State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 420 studies in Brain Concussion with a site in United States — 102 open to participants now, 123 under way, 5 of them phase 3. Brain Concussion · United States.
Among the 420 studies in Brain Concussion with a site in United States, this one is the 224th largest by planned enrollment of the 323 interventional ones that give a count, is one of 24 that started in 2026, is one of 265 with no phase, reaches primary completion later than 43 of the 122 other live ones, and was the 396th registered.
641 studies on the registry are indexed under Brain Concussion; 167 are open to participants now.
Browse Brain Concussion studies →102 of the 420 studies in Brain Concussion with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
HealthPartners Institute · Sites in United States
Ages 18–65
University of Michigan · Sites in United States
Ages 18+
Perception Dynamics Institute · Sites in United States
Ages 18–60
University of Colorado, Denver · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Brain Concussion studies recruiting now, 34 (30%) set no upper age limit and 73 (64%) stop at 75 or younger; 24 take children under 18; 38 take healthy volunteers.
This study: 18 Years to 27 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
420 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 29 · Phase 3 9 · Phase 4 5
First in 1998; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 63 across 449 interventional studies indexed under Brain Concussion.
Median enrollment 60 across the 323 interventional studies, 147 across the 96 observational. Of the 259 that completed or were terminated, 68 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 420 have an industry lead sponsor. The 10 most frequent:
Penn State University is the lead sponsor of 271 studies on the registry; 54 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Penn State University has 2 studies filed under Brain Concussion — fewer than ten, so there is no comparison to draw.
50 of the studies in Brain Concussion with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05320822University of North Carolina, Chapel HillA Pragmatic Rehabilitation Intervention: The Active Rehab Study | 2026-11-28 |
| NCT06109909VA Office of Research and DevelopmentPilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury | 2026-11-30 |
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT04708613David Okonkwo, MD, PhDUniversity of Pittsburgh Brain Health Initiative | 2026-12 |
Add all 50 to your calendar (.ics) → With an account.
Among the 420 studies in Brain Concussion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is being done to examine the benefits of a 28 day head cooling intervention on cognition, inflammation of the brain, sleep quality, menstrual symptom interaction, and mood in acutely concussed females. Brain cooling has been shown to cause temporary symptom relief after traumatic brain injury, but its implications for decreasing timeline of full concussion recovery, particularly in females during periods of confounding neuropsychological menstrual symptoms, remains unexplored.
Concussions are a form of mild traumatic brain injury (mTBI) that can lead to prolonged physical, cognitive, emotional, neuroinflammatory symptoms. An increase in IL-6 levels is seen due to neuroinflammation following mTBI. Following a concussion, females are more likely to experience sleep disturbances. This can impact the number of headaches and mood changes they experience. Emerging evidence suggests that hormonal fluctuations across the menstrual cycle may influence concussion recovery and symptoms specifically in the luteal phase.
Head cooling, or localized cranial hypothermia, has been explored as a therapeutic intervention to reduce neuroinflammation and cerebral metabolic demands following brain injury. Head cooling has been shown to reduce post-concussion symptoms recovery time and lessen the severity of symptoms like sleep disruptions, mood changes, and cognitive dysfunctions as well as decrease intracranial pressure. Recent research from our lab has also demonstrated that selective head cooling decreases depression symptoms and increases alpha wave power (measured via EEG). The gap that exists in the research is the effect that head cooling could have to help mitigate concussion symptoms specifically during the luteal phase of the menstrual cycle.
Thirty-two females, aged 18-27, will participate in this study (N=16 with acute concussion, N=16 healthy controls). Both sample groups will be randomly separated into placebo and head cooling intervention groups. The study will last the length of one pre-standardized menstrual cycle (28 days). The intervention group will receive 30-minute head cooling treatment, 5 days per week (Monday-Friday), while the placebo group will be instructed to continue normal daily activities without intervention. Participants will be asked to provide a blood sample on Day 1 and Day 28, which will be analyzed for serum concentration of Interluken-6 (IL-6), a neuroinflammatory biomarker. Also, on Day 1 and Day 28, participants will complete a brief cognitive testing battery that includes: the Psychomotor Vigilance Task (PVT), the Dual 2-Back, and the Stroop Task; as well as a brief psychological battery that includes: Beck's Depression Inventory-Fast Screen (BDI-fs), Hamilton Anxiety Rating Scale (HAM-A), and the Penn State Worry Questionnaire (PSWQ). Over the 28-day study timeline, participants will be asked to record their daily sleep using the free app, Consensus Sleep Diary (CSD) and record their daily menstrual cycle and symptoms using the free app, Clue, and record their daily concussion symptoms using a de-identified Qualtrics survey format Post-Concussion Symptom Scale (PCSS).
Visit 1 will occur on Day 1 of the study. Participants will be instructed to refrain from food, water, or brushing teeth for at least 30 minutes prior to their visit. At this time, the participants will be randomly assigned to the control or intervention group.
Participants will be asked to provide a blood sample, drawn by a registered nurse. This method requires the participants to have 5.0 mL of blood drawn. Samples will then be immediately stored in a marked freezer unit.
Next, the participants will be asked to complete a written history and demographics form, as well as the following mental health questionnaires: Beck's Depression Inventory-Fast Screen (BDI-fs), Hamilton Anxiety Rating Scale (HAM-A), and the Penn State Worry Questionnaire (PSWQ). After this, the subject will complete a computer-based cognitive testing battery that includes: the Psychomotor Vigilance Task (PVT), the Dual 2-Back, and the Stroop Task. These actions will only be completed out at the first visit (visit 1) and at the last visit (visit 2 for the control group, or visit 20 for the intervention group).
The subjects will also complete the Post-Concussion Symptom Scale (PCSS) during their first visit and will continue to do so daily until the last visit via a de-identified Qualtrics survey. On this daily survey participants will provide their given participant identification number, but not their name or any identifiable information.
The participant will then be informed about the Consensus Sleep Diary (CSD) app and the Clue app. They will create a de-identified account for each, which will be accessible by the study team for data collection purposes. Participants may download the application to their device or so use a personal computer so to access the applications and track their daily sleep and menstrual cycle \& symptoms.
Participants assigned to the control group will be finished with Visit 1 at this time. Participants in the head cooling condition (intervention group) will undergo a 30-minute session while seated in a quiet, dimly lit room, listening to soothing natural sounds, wearing a Welkins Arctic Cooling Cap V1.30. The cap will be applied at room temperature and positioned on the top of the head, secured with adjustable Velcro straps; it does not include a chin strap. A coolant line connects the cap to the cooling system, which, when activated, circulates chilled coolant through the cap. The temperature of the cap will decrease from room temperature to 33.0°F over approximately 2-3 minutes. The cap remains dry and does not produce condensation during use. Pilot testing has shown that the cap is generally comfortable, but if a participant reports any discomfort, the cap will be immediately removed and adjusted. Sessions can also be ended at the participant's request. Participants will be instructed to remain awake, avoid looking at screens, and relax as much as possible.
The total duration of the first visit will last approximately 45 minutes for the control group and 75 minutes for the intervention group.
Visit 2 -19; the intervention group will come in everyday Monday-Friday for 30 minutes of head cooling (as explained above). That is, 20 total visits, over a 28 day period.
The control group will proceed with normal daily life during this time. The control group's next visit, which will be their Visit 2 and final visit, will occur at the same time as the intervention group's final visit. That is, 28 day (4 weeks), or one standard menstrual cycle, after Visit 1.
Thus, Visit 2 for control will be the same as visit 20 for the intervention group, and will occur 28 days after Visit 1. This visit will be the same as Visit 1 for both groups, however no head cooling will be administered to either group on this day. Thus, this final visit will last approximately 25 minutes for everyone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, during which they will wear a Welkins Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur 5 days per week for 4 total weeks. Brain cooling treatment participants will also continue with their normally prescribed concussion recovery protocol as outlined by their outside clinicians.
Device: Brain Cooling
Control participants will maintain their normally prescribed concussion recovery protocol as outlined by their outside clinicians.
Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, during which they will wear a Welkins Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur 5 days per week for 4 total weeks.
Beck's Depression Inventory-Fast Screen
The Beck's Depression Inventory-Fast Screen is a 13-item subjective report of depression symptoms.
Time frame: The metrics will be assessed on pre-intervention (Day 1) and post-intervention (Day 28).
HAM-A
the HAM-A is a 14-item subjective report of anxiety symptoms.
Time frame: The metrics will be assessed pre-intervention (Day 1) and post-intervention (Day 28).
The Penn State Worry Questionnaire
The Penn State Worry Questionnaire is a 16-item subjective report of perceived worry.
Time frame: The metrics will be assessed pre-intervention (Day 1) and post-intervention (Day 28).
Psychomotor Vigilance Task (PVT)
The PVT is a very brief (\<1 min) test to assess reaction time and sustained attention.
Time frame: The metrics will be assessed pre-intervention (Day 1) and post-intervention (Day 28).
Dual 2-back Test
The Dual 2-back Test is a 72 second measure of working memory.
Time frame: The metrics will be assessed pre-intervention (Day 1) and post-intervention (Day 28).
Stroop Task
The Stroop task is a brief measure of selective attention, processing speed, and executive function
Time frame: The metrics will be assessed pre-intervention (Day 1) and post-intervention (Day 28).
Consensus Sleep Diary (CSD)
The CSD is a remote application that allows for description and tracking of metrics related to sleep quantity and quality.
Time frame: CSD will be recorded daily throughout the intervention (from Day 1 to Day 28).
Clue App
The Clue App is a qualitative journaling tool for recording menstrual cycle timeline and symptom severity.
Time frame: Clue entries will be recorded daily throughout the intervention (from Day 1 to Day 28).
Post-Concussion Symptom Scale (PCSS)
The PCSS is a 21 item concussion symptom self-scoring measure. Each item ranks a different concussion symptom category on a 0-6 scale.
Time frame: PCSS will be recorded daily throughout the intervention (from Day 1 to Day 28).
Plan to share: Undecided
Start is estimated for Jan 2026; primary completion for Jan 2027, 11 months later.
Of 249 non-industry interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 11 months is below that.
Counting every sponsor, half of 265 studies reached it within 28 months; a quarter within 19 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.